NASDAQ:ONTX

Onconova Therapeutics Stock Insider Trading

> Biotechnology

Buy ONTX

*Your capital is at risk

$24.16

+0.757 (+3.23%)

At Close: Jul 10, 2026

Onconova Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 3.03M and sold 52.77K ONTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	3.03M shares
● Sell	52.77K shares
86% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 14, 2024 Sell	Common Stock F-InKind	Guerin Mark Patrick CFO And COO	C-Suite Officer	2 591 Value: $2K
Mar 14, 2024 Sell	Common Stock F-InKind	Fruchtman Steven M President, Chief Executive Off	CEO / President	8 727 Value: $8K
Mar 13, 2024 Buy	Common Stock M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	8 666 Value: $0
Mar 13, 2024 Buy	Restricted Stock Units M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	8 666 Value: $0
Mar 13, 2024 Buy	Common Stock M-Exempt	Fruchtman Steven M President, Chief Executive Off	CEO / President	23 111 Value: $0
Mar 13, 2024 Buy	Restricted Stock Units M-Exempt	Fruchtman Steven M President, Chief Executive Off	CEO / President	23 111 Value: $0
Feb 07, 2024 Buy	Common Stock M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	6 900 Value: $0
Feb 07, 2024 Sell	Common Stock F-InKind	Guerin Mark Patrick CFO And COO	C-Suite Officer	2 443 Value: $2K
Feb 07, 2024 Buy	Restricted Stock Units M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	6 900 Value: $0
Feb 07, 2024 Buy	Common Stock M-Exempt	Fruchtman Steven M President, Chief Executive Off	CEO / President	21 320 Value: $0
Feb 07, 2024 Sell	Common Stock F-InKind	Fruchtman Steven M President, Chief Executive Off	CEO / President	9 212 Value: $6K
Feb 07, 2024 Buy	Restricted Stock Units M-Exempt	Fruchtman Steven M President, Chief Executive Off	CEO / President	21 320 Value: $0
Oct 02, 2023 Buy	Stock Option (right to purchase) A-Award	Moyo Victor M Chief Medical Officer	Officer	125 000 Value: $92.5K
Oct 02, 2023 Buy	Common Stock J-Other	Moyo Victor M Insider	Other	0 Value: $0
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Shoemaker Mary Teresa Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Stover Jack E Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Atadja Peter Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Clarke Trafford Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Mehta Viren Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Groopman Jerome Director	Director	66 468 Value: $67.8K
Aug 10, 2023 Buy	Stock Option (right to purchase) A-Award	Marino James J Director	Director	66 468 Value: $67.8K
Aug 03, 2023 Sell	Common Stock F-InKind	Guerin Mark Patrick CFO And COO	C-Suite Officer	1 422 Value: $1K
Aug 03, 2023 Sell	Common Stock F-InKind	Fruchtman Steven M President, Chief Executive Off	CEO / President	4 744 Value: $5K
Aug 02, 2023 Buy	Common Stock M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	4 750 Value: $0
Aug 02, 2023 Buy	Restricted Stock Units M-Exempt	Guerin Mark Patrick CFO And COO	C-Suite Officer	4 750 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ONCONOVA THERAPEUTICS INC

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with P...

Read Full Profile Here